Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
作者： Athanasios Dellis , Athanasios Papatsoris
DOI: 10.1586/14737167.2016.1123624
关键词:
摘要: Fortunately, novel agents are nowadays available for the management of patients with castration-resistant prostate cancer (CRPC). Denosumab is a new bone-protective agent, approved prevention and skeletal-related events. Studies have demonstrated that denosumab has better efficacy similar rate adverse effects in comparison zoledronic acid, which was standard agent. In present review we study cost-effectiveness CRPC.
sci-hub.se 参考文章(41)
Sonja Sorensen, Lorie Ellis, Ying Wu, Valerie Hutchins, John E. Linnehan, Mekré Senbetta, Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Journal of Managed Care Pharmacy. ,vol. 19, pp. 799- 808 ,(2015) , 10.18553/JMCP.2013.19.9.799
Fred Saad, Neal Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas A. Griffin, Peter De Porre, Anil Londhe, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302 European Urology. ,vol. 68, pp. 570- 577 ,(2015) , 10.1016/J.EURURO.2015.04.032
Benjamin A. Gartrell, Robert Coleman, Eleni Efstathiou, Karim Fizazi, Christopher J. Logothetis, Matthew R. Smith, Guru Sonpavde, Oliver Sartor, Fred Saad, Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options European Urology. ,vol. 68, pp. 850- 858 ,(2015) , 10.1016/J.EURURO.2015.06.039
Henry J. Henk, Satyin Kaura, Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan Journal of Medical Economics. ,vol. 15, pp. 175- 184 ,(2012) , 10.3111/13696998.2011.632044
Steven B Zeliadt, David F Penson, Pharmacoeconomics of available treatment options for metastatic prostate cancer. PharmacoEconomics. ,vol. 25, pp. 309- 327 ,(2007) , 10.2165/00019053-200725040-00004
Hind T. Hatoum, Swu-Jane Lin, Mathew R. Smith, Victoria Barghout, Allan Lipton, Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases Cancer. ,vol. 113, pp. 1438- 1445 ,(2008) , 10.1002/CNCR.23775
Roland Baron, Serge Ferrari, R. Graham G. Russell, Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. ,vol. 48, pp. 677- 692 ,(2011) , 10.1016/J.BONE.2010.11.020
Jeanny B Aragon-Ching, Unravelling the role of denosumab in prostate cancer. The Lancet. ,vol. 377, pp. 785- 786 ,(2011) , 10.1016/S0140-6736(11)60100-1
Allan Lipton, Karim Fizazi, Alison T. Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary E. Richardson, Salvatore Siena, Pablo Maroto, Michael Clemens, Boris Bilynskyy, Veena Charu, Philippe Beuzeboc, Michael Rader, Maria Viniegra, Fred Saad, Chunlei Ke, Ada Braun, Susie Jun, Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials European Journal of Cancer. ,vol. 48, pp. 3082- 3092 ,(2012) , 10.1016/J.EJCA.2012.08.002
Melina Arnold, Henrike E. Karim-Kos, Jan Willem Coebergh, Graham Byrnes, Ahti Antilla, Jacques Ferlay, Andrew G. Renehan, David Forman, Isabelle Soerjomataram, Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. European Journal of Cancer. ,vol. 51, pp. 1164- 1187 ,(2015) , 10.1016/J.EJCA.2013.09.002